NCT00240422View on ClinicalTrials.gov

Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

February 28, 2003

Study Completion Date

July 31, 2004

Conditions
Diabetes Mellitus, Type 2Hypertension
Interventions
DRUG

Telmisartan

DRUG

Ramipril

Trial Locations (6)

28041

Edificio de Medicina Comunitaria, Madrid

90402

Boehringer Ingelheim Investigational Site, Nuremberg

90471

Universität Erlangen-Nürnberg, Nuremberg

91054

Friedrich-Alexander-Universität, Erlangen

Unknown

Boehringer Ingelheim Investigational Site, Lyon

Boehringer Ingelheim Investigational Site, Montpellier

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY